Insulin sensitivity, glucose variability, body composition, and the GLP-1 era. What the trials show, how to read your own markers, and how to build durable metabolic health beyond the medication.
Evidence-tiered, AI-assisted, and fully disclosed.
Semaglutide and tirzepatide have reshaped obesity and type-2 diabetes care. Here is what the mechanism science and landmark trial programs reveal about their real-world effects.
Read article →Insulin resistance can be present for years before a type-2 diabetes diagnosis. Recognizing its early signals — and understanding which interventions have strong trial support — changes the window for intervention.
Read article →CGM devices are increasingly worn by metabolically healthy adults as wellness tools. Here is what the published data actually says about what CGM can and cannot tell someone without diabetes.
Read article →